{
  "id": "56c1f02aef6e39474100004b",
  "type": "factoid",
  "question": "Which interleukin is blocked by Siltuximab?",
  "ideal_answer": "Siltuximab is a monoclonal antibody that binds to interleukin-6 with high affinity and specificity.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21321981",
    "http://www.ncbi.nlm.nih.gov/pubmed/26392750",
    "http://www.ncbi.nlm.nih.gov/pubmed/20179212",
    "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
    "http://www.ncbi.nlm.nih.gov/pubmed/20699329",
    "http://www.ncbi.nlm.nih.gov/pubmed/25784388",
    "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
    "http://www.ncbi.nlm.nih.gov/pubmed/25294016",
    "http://www.ncbi.nlm.nih.gov/pubmed/25655379",
    "http://www.ncbi.nlm.nih.gov/pubmed/20808314",
    "http://www.ncbi.nlm.nih.gov/pubmed/21795409",
    "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
    "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
    "http://www.ncbi.nlm.nih.gov/pubmed/23432640",
    "http://www.ncbi.nlm.nih.gov/pubmed/21241278",
    "http://www.ncbi.nlm.nih.gov/pubmed/21216930",
    "http://www.ncbi.nlm.nih.gov/pubmed/24922005",
    "http://www.ncbi.nlm.nih.gov/pubmed/22828917",
    "http://www.ncbi.nlm.nih.gov/pubmed/23913484"
  ],
  "snippets": [
    {
      "text": "This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26392750",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25655379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294016",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Siltuximab is a monoclonal antibody that binds to interleukin (IL)-6 with high affinity and specificity; C-reactive protein (CRP) is an acute-phase protein induced by IL-6. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21241278",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24922005",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21216930",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179212",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21321981",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828917",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC) patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828917",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432640",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: These results demonstrated that siltuximab effectively block the IL-6 signaling pathways, which. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: These results show that siltuximab effectively block the IL-6 signaling pathways and IL-6-induced gene expression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20699329",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808314",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To study the effects of siltuximab on the interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (Stat3) signaling pathway in ovarian epithelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results demonstrated that siltuximab effectively block the IL-6 signaling pathways,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results show that siltuximab effectively block the IL-6 signaling pathways and IL-6-induced gene expression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20699329",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The IL6 regulation of IRF9 was confirmed at mRNA and protein levels by quantitative real-time PCR and western blot respectively in both cell lines and could be blocked by the anti-IL6 antibody Siltuximab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC) patients. We assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828917",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results demonstrated that siltuximab effectively block the IL-6 signaling pathways, which.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC) patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828917",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman&apos;s disease..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment of ovarian cancer cells with siltuximab reduced constitutive cytokine and chemokine production and also inhibited IL-6 signaling, tumor growth, the tumor-associated macrophage infiltrate and angiogenesis in IL-6-producing intraperitoneal ovarian cancer xenografts.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795409",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007378",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018123"
  ],
  "exact_answer": "interleukin-6"
}